NCT07312526 2026-04-15
Shanghai Clinical Cohort - Esophageal Cancer
Shanghai Chest Hospital
Completed
Clinical Trials
13 trialsNCT07519486 2026-04-15
INS-ESCC-CT
Sichuan University
Phase 2 Recruiting
NCT03801876 2026-04-03
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NRG Oncology
Phase 3 Recruiting
NCT07505186 2026-04-01
Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT05706558 2026-03-09
Retrospective Review of Esophageal Cancer at MSKCC
Memorial Sloan Kettering Cancer Center
Recruiting
NCT07449208 2026-03-04
Registry Study of People Who Are Having an Esophagectomy and Are at High Risk of Anastomotic Leak
Memorial Sloan Kettering Cancer Center
Recruiting
NCT07317609 2026-01-05
Endosurgery-02
Shanghai Zhongshan Hospital
Phase 1 Recruiting
NCT05659251 2025-12-02
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07244978 2025-12-02
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT02558504 2025-10-02
HARMONI
Hospices Civils de Lyon
Phase 4 Completed
NCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT04666090 2025-05-15
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting